AI-generated · cited to primary sources · not investment advice · How we research
Sagility
Our verdict on Sagility isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company has successfully deployed 25 distinct AI use cases, surpassing the previously mentioned 18 use cases and the 15 additional cases in progress. (3 exceeded across 3 tracked commitments)
“Sagility is advancing AI orchestration through SmarTec and Synchrony to drive smarter, end-to-end operations and measurable outcomes”
The company reported 9M FY26 revenue growth of 29.2% (24.2% at Constant Currency), which is significantly ahead of the full-year guidance of 21% plus. (4 exceeded, 1 met across 5 tracked commitments)
“Ongoing impact on overall Margins is likely to be 0.2% of Revenues.”
See the full cited Management analysis of Sagility
How durable is the business?
Sagility is aggressively expanding its AI moat, having deployed 18 AI use-cases across 8 clients with 15+ more in development, focusing on clinical reviews and contract validation. (3 expanding)
“Sagility is advancing AI orchestration through SmarTec and Synchrony to drive smarter, end-to-end operations and measurable outcomes”
Sagility is aggressively deploying AI use cases (18 currently live) to drive non-linear growth, moving away from pure FTE-based models to transaction-based models where they can retain efficiency gains. (2 expanding)
“currently, we've deployed about 18 AI-based use cases for eight of our existing clients. We're also working on 15 additional use cases... the relationship between revenue and headcount will start to diminish.”
See the full cited Business Model analysis of Sagility
Where does growth come from?
New business wins are accelerating with a significant $32 million in potential annual contract value (ACV) secured in a single quarter, including major wins in the $5B-$12B client range. (5 accelerating across 5 signals)
“Top 3 client %: 59.9% (FY26) vs 72.4% (FY23). Top 3 client CAGR of 9.1% (in CC) over FY23 to FY26. Overall CAGR of 16.2% (in CC) over FY23 to FY26.”
The company is seeing a significant acceleration in seasonal revenue due to a favorable Open Enrollment (OE) season, leading to an upward revision of full-year revenue guidance. (1 accelerating, 1 new trend across 2 signals)
“CMS finalized Medicare Advantage Rates at 2.48% Y-o-Y increase... Proposals that focus on cost takeout in administrative functions and improving STARs ratings resonate with payers”
See the full cited Future Growth analysis of Sagility
What could break the thesis?
Seasonality is intensifying following the BroadPath acquisition, with Q3 now expected to be significantly larger than previous years due to Medicare Advantage cycles. (5 intensifying, 1 high-severity)
“In FY '26, payers contributed 89.7% of revenues, while providers contributed 10.3%.”
The Payer vertical remains the dominant revenue driver at 88.4% of the mix, showing a stable but high concentration. Management is aggressively growing the Provider segment (up 34.5% YoY) to diversify. (1 stable, 3 easing, 1 high-severity)
“The notable point here is our top three concentration has fallen below 60%.”
See the full cited Risk analysis of Sagility
Read the full thesis on Sagility
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.